Danaher Corporation is a global science and technology company that designs, manufactures, and markets a diverse range of industrial and healthcare products and solutions
The company's operations are organized into several segments, including life sciences, diagnostics, dental, and environmental and applied solutions. Danaher focuses on advancing vital sciences and technologies through innovative products and services that enhance the quality of life. With a commitment to customer satisfaction, the company leverages its extensive expertise in engineering and manufacturing to deliver reliable and efficient solutions across various industries, helping to drive improved outcomes in healthcare, environmental monitoring, and industrial processes.
Diversified science and technology company Danaher (NYSEDHR) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 2.1% year on year to $6.54 billion. Its non-GAAP profit of $2.14 per share was 1.3% below analysts’ consensus estimates.
Total earnings for the 112 S&P 500 companies that have reported results are up +10.8% from the same period last year on +5.5% higher revenues, with 80.4% beating EPS estimates and 68.8% beating revenue estimates.
Aldevron, a global leader in the production of DNA, RNA and protein, has launched its latest innovation, Alchemy™ cell-free DNA technology. This revolutionary technology represents a significant advancement in synthetic DNA manufacturing, offering a cell-free, enzymatic process to generate linear DNA (linDNA) templates for in vitro transcription (IVT) synthesis of mRNA molecules.
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and the reasons why the stocks may be drawing attention.
BofA upgrades Danaher and Revvity, predicting a mixed but improving outlook for life sciences tools in fiscal year 2025 amid ongoing market challenges.